Entera Bio Ltd.

NasdaqCM:ENTX Stock Report

Market Cap: US$80.1m

Entera Bio Management

Management criteria checks 2/4

Entera Bio's CEO is Miranda Toledano, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is $950.00K, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $240.88K. The average tenure of the management team and the board of directors is 2.4 years and 6.1 years respectively.

Key information

Miranda Toledano

Chief executive officer

US$950.0k

Total compensation

CEO salary percentage35.6%
CEO tenure2.4yrs
CEO ownership0.3%
Management average tenure2.4yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Dec 07
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

May 31
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Feb 15
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Oct 13
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Aug 11

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Jun 10
We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Jan 21
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05
Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

CEO Compensation Analysis

How has Miranda Toledano's remuneration changed compared to Entera Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$950kUS$338k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$795kUS$231k

-US$13m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$82kn/a

-US$12m

Compensation vs Market: Miranda's total compensation ($USD950.00K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Miranda's compensation has increased whilst the company is unprofitable.

CEO

Miranda Toledano (47 yo)

2.4yrs

Tenure

US$950,000

Compensation

Ms. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since November 2021.She has b...

Leadership Team

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director2.4yrsUS$950.00k0.30%
$ 240.9k
Dana Yaacov-Garbeli
Chief Financial Officer2.4yrsUS$311.00k0.15%
$ 123.1k
Hillel Galitzer
Chief Operating Officer10.8yrsUS$459.00k0.093%
$ 74.2k
Gregory Burshtein
Chief of Research & Developmentless than a yearno data0.14%
$ 108.7k

2.4yrs

Average Tenure

46.5yo

Average Age

Experienced Management: ENTX's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director6.3yrsUS$950.00k0.30%
$ 240.9k
Gerald Lieberman
Independent Chairman of the Board10.7yrsUS$130.97k0.79%
$ 631.4k
Gerald Ostrov
Independent Director5.9yrsUS$120.97k0.11%
$ 84.6k
Sofia Ish-Shalom
Member of Scientific Advisory Boardno datano datano data
Yonatan Malca
Independent Director13.9yrsUS$124.97k0.11%
$ 84.9k
Sean Ellis
Independent Director5.5yrsUS$117.47k0.35%
$ 277.6k
Socrates Papapoulos
Member of Scientific Advisory Boardno datano datano data
John Bilezikian
Member of Scientific Advisory Boardno datano datano data
Maria Brandi
Member of Scientific Advisory Boardno datano datano data
Bart Clarke
Member of Scientific Advisory Boardno datano datano data
Felicia Cosman
Member of Scientific Advisory Board2.1yrsno datano data
William Fraser
Member of Scientific Advisory Boardno datano datano data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Board: ENTX's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:22
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
null nullCG Capital
Raghuram SelvarajuH.C. Wainwright & Co.